Beginning with our family of NSAIDs, we are building a broad drug pipeline, expanding beyond pain and inflammation to include gastrointestinal and aging-related diseases.
Antibe’s drug pipeline targets large markets in non-addictive pain management. Our lead drug, otenaproxesul (formerly known as ATB-346), has demonstrated gastrointestinal safety as well as efficacy in the treatment of osteoarthritis, a condition affecting 300 million people worldwide. Our second pipeline drug is designed to replace opioids for peri-operative pain, directly addressing a worldwide public health crisis. In the longer term, we will exploit our platform to create drugs that address a range of inflammation-based diseases.
We generate revenue through our wholly owned subsidiary, Citagenix Inc., a worldwide distributor of regenerative medicine products for dentists, periodontists and oral surgeons.
http://www.antibethera.com (OTCQX .. ATBPF)
Corporate Presentation
https://antibethera.com/wp-content/uploads/2021/03/Antibe-Corporate-Presentation-March-2021.pdf
|
